Program
Caffeine
Also written as “caffeine”, “ibuprofen + caffeine” and “Paracetamol and Caffeine”.
Its studies are mostly in Pain · Neoplasms · Pain, Postoperative · Common Cold · Obesity, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 60 open or running | phase 3since Aug 22, 2013 | Jun 13, 2013 | none ahead |
| GlaxoSmithKline | 50 open or running | phase 4since Nov 3, 2011 | Mar 1, 2007 | none ahead |
| Pfizer | 20 open or running | phase 3since Aug 8, 2016 | Aug 8, 2016 | none ahead |
| Hypera Pharma | 10 open or running | phase 3since Jul 28, 2010 | Jul 28, 2010 | none ahead |
| Novartis | 10 open or running | phase 4since Nov 23, 2010 | Nov 23, 2010 | none ahead |
| Sanofi | 10 open or running | phase 3since Aug 31, 2011 | Aug 31, 2011 | none ahead |
Also a collaborator on its studies: medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Mar 1, 2007.
- Nov 23, 2010Novartis's first study: phase 4 study in PainNew to NovartisNovartis · NCT01248468 · 752 enrolled · United States
- Aug 31, 2011Sanofi's first study: phase 3 study in PainNew to SanofiSanofi · NCT01426971
- Nov 3, 2011Phase 4 study in Common ColdGlaxoSmithKline · NCT01466348 · 72 enrolled · United Kingdom
- Sep 13, 2012Phase 3 study in Common ColdGlaxoSmithKline · NCT01686646 · 240 enrolled · United Kingdom
- Apr 25, 2013Phase 3 study in PainGlaxoSmithKline · NCT01842633 · 365 enrolled · United States
- Jun 13, 2013Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT01879371 · 36 enrolled · Germany
- Aug 22, 2013Phase 3 study in Pain, PostoperativeBoehringer Ingelheim · NCT01929031 · 562 enrolled · United States
- Jul 7, 2014Phase 3 study in Migraine DisordersBoehringer Ingelheim · NCT02183688 · 1,889 enrolled
- Dec 10, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02629354 · 36 enrolled · South Africa
- Aug 8, 2016Pfizer's first study: phase 3 study in PainNew to PfizerPfizer · NCT02863575 · 374 enrolled · United States
- Sep 19, 2016Phase 4 study in PainGlaxoSmithKline · NCT02974114 · 21 enrolled · United Kingdom
- Nov 17, 2016Phase 3 study in Back PainBoehringer Ingelheim · NCT03003000 · 635 enrolled · Germany, Russian Federation
- Dec 3, 2020Phase 1 study in Healthy ParticipantsPfizer · NCT04655040 · 12 enrolled · United States
- Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741385 · 4 enrolled · Germany
TargetBeta
“Adenosine receptor antagonist; Adenosine receptor antagonist”ChEMBL 37, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05741385Liver Cirrhosis · Germany | – | Completed | Boehringer Ingelheim | Aug 9, 2024 | 4 |
| NCT04655040Healthy Participants · United States | 1 | Completed | Pfizer | Mar 5, 2021 | 12 |
| NCT03003000Back Pain · Germany, Russian Federation | 3 | Completed | Boehringer Ingelheim | Sep 24, 2017 | 635 |
| NCT02974114Pain · United Kingdom | 4 | Terminated | GlaxoSmithKline | Feb 6, 2017 | 21 |
| NCT02863575Pain · United States | 3 | Completed | Pfizer | Apr 6, 2018 | 374 |
| NCT02629354Healthy · South Africa | 1 | Completed | Boehringer Ingelheim | Jan 2016 | 36 |
| NCT02183688Migraine Disorders | 3 | Completed | Boehringer Ingelheim | Jan 2003 | 1,889 |
| NCT01929031Pain, Postoperative · United States | 3 | Completed | Boehringer Ingelheim | Mar 2014 | 562 |
| NCT01879371Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2013 | 36 |
| NCT01842633Pain · United States | 3 | Terminated | GlaxoSmithKline | Mar 31, 2015 | 365 |
| NCT01686646Common Cold · United Kingdom | 3 | Completed | GlaxoSmithKline | Nov 2012 | 240 |
| NCT01466348Common Cold · United Kingdom | 4 | Completed | GlaxoSmithKline | Apr 2011 | 72 |
| NCT01426971Pain | 3 | Withdrawn | Sanofi | Jun 2013 | 0 |
| NCT01248468Pain · United States | 4 | Completed | Novartis | Mar 2011 | 752 |
| NCT01172405Headache | 3 | UNKNOWN | Hypera Pharma | Oct 2012 | 144 |
| NCT00443170Anemia · Australia | 1 | Completed | GlaxoSmithKline | 90 |
How it is read
Names in the registry
- “Caffeine”, 11 entries
- “caffeine”, 4 entries
- “ibuprofen + caffeine”, 3 entries
- “Paracetamol and Caffeine”, 2 entries
- “Cocktail (Warfarin/Caffeine/Midazolam)”, 1 entry
Conditions, from the studies’ own filings
- Pain, 5 studies
- Neoplasms, 2 studies
- Pain, Postoperative, 2 studies
- Common Cold, 2 studies
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.